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ABSTRACT
Background HIV self- testing (HIVST) has been shown 
to be acceptable, feasible and effective in increasing HIV 
testing uptake. Novel testing strategies are critical to 
achieving the UNAIDS target of 95% HIV- positive diagnosis 
by 2025 in South Africa and globally.
Methods We modelled the impact of six HIVST kit 
distribution modalities (community fixed- point, taxi 
ranks, workplace, partners of primary healthcare (PHC) 
antiretroviral therapy (ART) patients), partners of pregnant 
women, primary PHC distribution) in South Africa over 20 
years (2020–2039), using data collected alongside the 
Self- Testing AfRica Initiative. We modelled two annual 
distribution scenarios: (A) 1 million HIVST kits (current) 
or (B) up to 6.7 million kits. Incremental economic costs 
(2019 US$) were estimated from the provider perspective; 
assumptions on uptake and screening positivity were 
based on surveys of a subset of kit recipients and 
modelled using the Thembisa model. Cost- effectiveness of 
each distribution modality compared with the status- quo 
distribution configuration was estimated as cost per life 
year saved (estimated from life years lost due to AIDS) and 
optimised using a fractional factorial design.
Results The largest impact resulted from secondary 
HIVST distribution to partners of ART patients at PHC (life 
years saved (LYS): 119 000 (scenario A); 393 000 (scenario 
B)). However, it was one of the least cost- effective 
modalities (A: $1394/LYS; B: $4162/LYS). Workplace 
distribution was cost- saving ($52–$76 million) and 
predicted to have a moderate epidemic impact (A: 40 000 
LYS; B: 156 000 LYS). An optimised scale- up to 6.7 million 
tests would result in an almost threefold increase in LYS 
compared with a scale- up of status- quo distribution 
(216 000 vs 75 000 LYS).
Conclusion Optimisation- informed distribution has the 
potential to vastly improve the impact of HIVST. Using this 
approach, HIVST can play a key role in improving the long- 
term health impact of investment in HIVST.
INTRODUCTION
South Africa has the highest number of 
HIV infections worldwide, with an estimated 
7.8 million people living with HIV (PLHIV) 
and 5.0 million on antiretroviral therapy 
(ART) in 2019.1 Despite having the largest 
ART programme in the world, over 23% of 
all deaths in South Africa in 2019 were AIDS- 
related.2 HIV transmission and AIDS- related 
deaths can be greatly reduced by identifying 
PLHIV who are unaware of their HIV status 
early, linking all PLHIV to ART and retaining 
them in care.3 The South African government 
is dedicated to meeting the UNAIDS 95-95-95 
fast- track targets by 2025,4 which aim to have 
Key questions
What is already known?
 ► HIV self- testing (HIVST) is an acceptable and feasible 
testing strategy that is also effective in increasing 
HIV testing uptake.
 ► Testing strategies which focus on high yield popu-
lations (eg, female sex workers) and high- volume 
distribution modalities (eg, taxi ranks and workplac-
es) have been found to be more cost- effective than 
some community- based or any facility- based testing 
strategies.
What are the new findings?
 ► Secondary distribution to partners of antiretroviral 
therapy patients has the largest impact in terms of 
saving life years lost due to AIDS; however, it is one 
of the least cost- effective strategies.
 ► Taxi rank and workplace distribution is the most 
cost- effective, even cost- saving of strategies.
 ► An optimisation- informed distribution of scaling up 
HIVST can greatly improve the impact of HIVST and 
result in a more cost- effective strategy compared 
with a status quo distribution of scaling up HIVST.
What do the new findings imply?
 ► Determining the optimal mix of HIVST kit distribution 
is crucial in ensuring the most effective and cost- 
effective strategy for national roll- out of HIVST.
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95% of PLHIV diagnosed, 95% of those diagnosed on 
ART and 95% of those on ART virally suppressed by 
2025. In 2017, a HIV household survey showed that 85% 
of South African PLHIV aged 15–64 years had been 
diagnosed, although men had a lower rate of diagnosis 
compared with women (80% vs 89%, respectively).5 
Increasing the uptake of HIV testing services (HTS) by 
introducing novel testing strategies is critical to achieving 
the UNAIDS target to diagnose 95% of PLHIV in the 
coming years.
In order to expand HIV testing coverage, the South 
African National Department of Health (NDoH) has 
implemented community- based testing to accompany 
existing conventional HTS, which is most frequently 
conducted at primary healthcare (PHC) clinics. Recently, 
HIV self- testing (HIVST) technology has been intro-
duced to give people the opportunity to self- diagnose 
their HIV status. HIVST involves a person being able to 
privately collect their own specimen (most often oral 
fluid), performing the rapid diagnostic test and inter-
preting the result themselves, either assisted by HIVST 
distribution staff or unassisted.6 Recent studies in sub- 
Saharan Africa, including South Africa, have shown that 
HIVST is acceptable, feasible and effective in increasing 
HIV testing uptake,7–9 providing an alternative testing 
strategy that can overcome sociostructural barriers associ-
ated with conventional HTS in a clinic setting, including 
the stigma associated with accessing testing and limited 
hours of clinic availability.10
Furthermore, many health services have been disrupted 
due to COVID-19 as governments across high HIV preva-
lence countries instituted lockdowns and other forms of 
restrictions to curb the spread of COVID-19.11 Though 
many of the restrictions have since been lifted, there 
remains a concern that with the pandemic still ongoing, 
people might be reluctant to attend PHC clinics for 
HIV testing. For this reason, US President’s Emergency 
Plan for AIDS Relief (PEPFAR) and PEPFAR- supported 
partners have recently recommended scaling up decen-
tralised access to HIVST.12 Since 2016, the Unitaid- 
funded Self- Testing AfRica (STAR) Initiative started 
distributing HIVST kits through a variety of approaches/
modalities in Malawi, Zambia and Zimbabwe, and later 
expanded to eSwatini, Lesotho and South Africa. Coor-
dinated economic analyses alongside this roll- out found 
that the cost per kit distributed (in 2019 US$) was $8.91 
in Malawi, $14.70 in Lesotho, $14.90 in Zimbabwe and 
$17.70 in Zambia using community- based distribution 
strategies,13 14 $12.82 in circumcision clinics in Zambia14 
and $8.66 in Malawi, $9.15 in Zimbabwe, $5.37 in Zambia 
and $13.40 in South Africa when kit distribution was 
integrated into public primary care facilities.15 A cost- 
effectiveness analysis of an array of community- based 
distribution approaches and settings in Sub- Saharan 
Africa showed these can be cost- effective if implementa-
tion is targeted based on HIV prevalence and health bene-
fits, and if costs are considered over a relatively long time 
horizon.16 In our analysis of South Africa’s distribution 
programme, we found that facility- based distribution 
modalities had on average higher cost per kit distributed 
than community- based distribution approaches, which 
was unlike observations in Zambia and Zimbabwe.17 18
Previous modelling work by our team in 2019 using 
preliminary cost and effectiveness data on HIVST from 
other settings, showed that out of ten testing modalities 
analysed, HIVST combined with home- based testing 
would have the greatest impact on the proportion of 
PLHIV who are diagnosed, increasing the fraction of 
diagnosed PLHIV to 96.5% by 2030 and would be highly 
cost- effective compared with currently funded HIV inter-
ventions.19 More recently, using data on intermediate 
outcomes such as person screened positive, tested posi-
tive in confirmatory testing and initiated on ART from 
the STAR- supported HIVST roll- out in South Africa, we 
established that testing strategies which focus on high 
yield populations such as female sex workers and high- 
volume distribution modalities such as taxi rank and 
workplace distribution were more cost- effective than 
other community- based or any of the facility- based testing 
strategies.18
This work is an update to our previous work, using data 
collected under the STAR Initiative to inform both effec-
tiveness and cost parameters in the Thembisa model,1 
in order to model the impact and cost- effectiveness of 
different HIVST distribution modalities over a 20- year 
time horizon (2020–2039) and, based on these outcomes, 
determine the highest impact and most cost- effective 




To assess the epidemiological impact of different testing 
strategies, we used the Thembisa model, a deterministic 
compartmental model set up to simulate HIV testing in 
South Africa.20 The model stratifies the population by 
sex and individual age and further divides the popula-
tion into a number of sexual behaviour risk groups. Previ-
ously, the model simulated three HIV testing modalities: 
testing through antenatal clinics, testing of patients with 
opportunistic infections and ‘general’ HIV testing. For 
each modality, rates of testing uptake are specified by age 
and sex, based on routine testing data and survey data on 
the proportions of adults who had ever been tested for 
HIV.20 21 All individuals are stratified according to their 
HIV testing history, into one of three compartments: 
never tested for HIV, previously tested but not diagnosed 
positive and diagnosed positive. Newly diagnosed indi-
viduals are assigned a probability of starting ART in the 
month of diagnosis, and a lower monthly rate of ART 
initiation is assumed for those who do not start ART in 
the month of diagnosis. The model allows for rediagnosis 
of previously diagnosed individuals, with relative rates of 
testing in previously diagnosed and treated individuals 
being set in such a way that the model matches historic 
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trends in HIV testing yields (declining from 25.8% in 
2004–2005 to 6.25% in 2018–201922). A more complete 
description of the model is provided elsewhere.1
For this analysis, we modelled the impact of six HIVST 
distribution modalities (fixed- point, taxi ranks, work-
place, secondary distribution to partners of ART patients 
at PHC, secondary distribution to partners of pregnant 
women at PHC, primary PHC distribution using Them-
bisa). A more detailed description of each modality is 
provided in the online supplemental appendix table S1, 
but briefly- fixed- point distribution involves testing tents 
set up near busy, preselected locations within communi-
ties. Taxi rank distribution involves distributing HIVST 
kits in densely populated public taxi ranks and train 
stations. Facility- based modalities such as secondary 
distribution through pregnant women and ART patients 
focused on the individuals taking the HIVST kits to their 
partners, while primary PHC is focused on the individual 
using the HIVST kit for themselves. Workplace distribu-
tion involved primary and secondary distribution in large 
male- dominated workplaces in industries such as manu-
facturing, mining, construction and so on.
The impact of HIVST in Thembisa was parameterised 
using data from the STAR initiative for each of the six 
modalities that were incorporated into the model, with 
the exception of primary distribution to PHC (which was 
conducted by implementing partners and not PHC staff 
in STAR). Surveys of a subset of 4% of HIVST recipients 
(n=40 834), conducted telephonically at 2- week, 4- week 
and 6- week intervals postdistribution, provided informa-
tion on the numbers of tests used, the age and sex profile 
of recipients, the self- reported test results (for those test 
kits that were used) and the proportions of those diag-
nosed positive who subsequently started ART, for each 
of the first five HIVST models. For each of these five 
models, the Thembisa assumptions about the age and sex 
profile of testers was set to match (approximately) that 
observed in the STAR data, but because the STAR data 
are not nationally representative and because HIV prev-
alence in South Africa is highly heterogeneous, we did 
not attempt to match the self- reported fraction of HIVST 
results that were positive (more detailed information is 
supplied in the online supplemental appendix). Model 
assumptions about test wastage (distributed HIVST kits 
which were reportedly not used) were also set to match 
those observed in the STAR data, although these could 
not be reliably determined in the case of the secondary 
distribution models, as many of the interviewed individ-
uals did not know if their partner had actually used the 
test. A more detailed description of each modality and 
the self- testing extensions to the model is provided in the 
online supplemental appendix.
Data for the sixth model, primary distribution to PHC 
clients, were not based on STAR data as the only models 
supported by STAR in South Africa were non- integrated 
(ie, using stand- alone distribution staff rather than clinic 
staff) and as such not representative of likely routine 
roll- out. Because we lacked data on the uptake of HIVST 
in primary PHC, we assumed that the patterns of uptake 
would be the same as for conventional facility- based 
HTS, with primary PHC distribution of HIVST effectively 
replacing a proportion of the HIV testing in PHC. To 
ensure this distribution modality was representative of 
how it would be conducted within the PHC, we assumed 
the same screening positivity as conventional HTS and 
used the results of previous cost analyses work of conven-
tional HTS at PHC level.19
Model outcomes reported are life years lost due to 
AIDS, HIV infections averted and AIDS deaths over 20 
years (2020–2039). HIV infections are averted both as a 
result of reduced infectiousness of individuals on ART 
and an assumed 56% reduction in unprotected sex after 
HIV diagnosis.1 No specific linkage to prevention services 
(or change in sexual behaviour) is assumed for people 
who test negative. Life years lost are calculated with refer-
ence to the life expectancies obtained from the West 
Level 26 lifetable.23
Cost analysis
To aid comparability across countries, the methods for 
the analysis of cost and outcomes of HIVST distribu-
tion through the six modalities were similar to the other 
economic analyses under STAR and are described in 
detail in Matsimela et al.18 Briefly, costs were estimated 
from the provider perspective using a detailed expend-
iture analysis complemented by activity- based observa-
tions (time in motion analysis) and micro- costing and 
included capital cost items such as start- up training, sensi-
tisation and equipment, as well as recurrent cost items 
such as personnel, test kits, other supplies, transporta-
tion, building operation and maintenance. Research 
costs and other costs that were only relevant to STAR and 
not related to routine implementation were excluded. To 
align the cost of primary HIVST distribution at PHC more 
closely with services offered within PHC, the cost per test 
kit distributed through this modality was estimated based 
on ingredients and prices adapted from previous work.19 
Capital costs were annualised over the 2 years’ duration 
of the project using a 3% discount rate, in keeping with 
the methods used in other countries.
In order to capture downstream programmatic 
effects, we modelled the impact of HIVST distribution 
on the cost and impact of the entire South African HIV 
programme over a 20- year time horizon; we included, 
among others, the cost of ART, medical male circum-
cision, condom distribution, prevention of mother- to- 
child transmission and conventional HTS with rapid 
tests through both facility- based and mobile testing 
modalities.24 Additional information of costs of other 
interventions included in the HIV programme are 
shown in online supplemental appendix table S2. Costs 
are presented undiscounted and converted to 2019 US 
dollars (US$) using the period average of 14.45 South 
Africa Rand (ZAR)=1 US$.25
4 Jamieson L, et al. BMJ Global Health 2021;6:e005598. doi:10.1136/bmjgh-2021-005598
BMJ Global Health
SCENARIOS
We consulted with a stakeholder panel of experts from 
the National Department of Health and from research 
organisations focused on HIVST regarding their 
expected outlook for HIVST distribution for South Africa 
beyond the STAR initiative, specifically for distribution 
through the six different modalities under analysis. The 
result constitutes our baseline scenario, a status- quo 
distribution, with 60% of HIVST kits assigned to primary 
PHC distribution, 20% to workplace distribution, 7% to 
secondary distribution to partners of women attending 
antenatal care (ANC) at PHC, 5% through fixed point 
distribution in communities, 5% to taxi rank distribution 
and 3% to secondary distribution to partners of ART 
patients at PHC. For our main analysis, we included two 
overarching coverage scenarios, defined by the number 
of HIVST distributed annually. Scenario A assumes that 
1 million HIVST kits will be distributed annually, in 
keeping with the current volumes of programme imple-
mentation, while Scenario B represents a target volume, 
scaling up to a maximum of 6.7 million HIVST kits distrib-
uted annually by 2030 (equivalent to replacing 40% of 
conventional HTS). The consultation also resulted in 
choosing a target population for each of the six HIVST 
distribution modalities as well as a ‘feasible maximum’, 
that is, a maximum number of people in each target 
population who can feasibly be screened for HIV with 
HIVST (see online supplemental appendix table S1).
Cost effectiveness analysis
To calculate the incremental cost- effectiveness of each 
HIVST distribution modality in turn, we assumed that 
100% of available HIVST kits would be distributed 
through one of the six distribution modalities in turn, 
for both coverage scenarios A and B. We estimated the 
incremental cost of HIVST as the change in the cost of 
the entire HIV programme and calculated the incre-
mental cost per HIV infection averted, cost per life year 
saved and cost per AIDS death averted over the 20- year 
time period, incremental to the status quo distribution of 
1 million HIVST.
Optimisation
We used a fractional factorial design to determine the 
optimal set of configurations between the different 
HIVST distribution modalities, resulting in the largest 
epidemiological impact and the most cost- effective 
configuration. This analysis was performed under both 
coverage scenarios A (1 million HIVST kits annually) and 
B (6.7 million HIVST kits annually), where we modelled 
all possible combinations of modalities at set increments, 
constrained only by the feasible maximum number of 
target population members reached in each modality. 
We compared all model runs to the status quo distribu-
tion of 1 million HIVST annually. We present different 
distributions across the different HIVST modalities and 
the impact on life years saved (LYS) and corresponding 
cost- effectiveness. Additional results regarding the 
impact on HIV infections averted are presented in the 
online supplemental appendix figures S1 and S2. We 
additionally compared the optimal distribution of HIVST 
in Scenario B to a scenario where the current status 
quo distribution of test kits was scaled up to meet the 
6.7 million HIVST target. Additional analyses for both 
scenarios A and B were conducted in which the baseline 
scenarios containing no HIVST are given in the online 
supplemental appendix figures S3 and S4.
Patient and public involvement
Patients were not directly involved in this study; this anal-





After accounting for uptake, the number of HIVST kits 
used ranges between 0.5 and 1.0 million kits across the 
six modalities (table 1). Compared with the status quo 
distribution of HIVST (table 1), primary distribution of 
all 1 million HIVST kits annually through PHC was domi-
nated, due to the lower positivity yields compared with 
the HIVST modalities included in the status quo distribu-
tion, increasing new HIV infections and life years lost due 
to AIDS over 20 years (depicted as negative infections 
averted or LYS) (table 2). The distribution strategy with 
the highest epidemiological impact with respect to saving 
life years, compared with the status quo, was distributing 
all HIVST kits to partners of PHC ART patients, which 
saved 119 000 (0.3%) life years. All remaining distribu-
tion modalities (fixed point, taxi ranks, secondary distri-
bution to partners of ANC clients, workplaces) were more 
effective than the status quo distribution and were esti-
mated to save between 40 000 and 63 000 (0.1%–0.2%) 
life years and averted 9000–28 000 (0.4%–1.1%) HIV 
infections over 20 years.
Scenario B
When scaling up the number of HIVST to 6.7 million 
kits distributed annually by 2030, exclusive primary 
distribution to PHC clients was dominated (table 2). 
Secondary distribution through PHC ART patients had 
the highest impact, saving 393 000 (1.1%) life years and 
averting 112 000 (4.3%) new HIV infections over 20 years 
(table 2), while fixed point and workplace distribution 
modalities had a moderate impact (205 000; 0.6% and 
156 000; 0.4% LYS, respectively). Distributing all kits 
through taxi ranks and partners of ANC clients had the 
least impact of all distribution modalities (98 000; 0.3% 
and 66 000; 0.2% LYS, respectively).
Costs
Scenario A
Due to the lower cost per test kit distributed, workplace 
distribution was estimated to be cost- saving compared 
with the status quo, saving an estimated $76 million over 
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20 years (table 2). HIVST distribution to partners of 
PHC ART patients and ANC clients were the most costly 
of the distribution strategies ($166 million each over 20 
years), while distribution through taxi ranks and fixed 
point distribution had an incremental cost to the HIV 
programme of $9 million and $44 million, respectively.
Scenario B
Compared with the status quo, distribution of 6.7 million 
HIVST kits through workplaces was cost- saving 
($52 million over 20 years) (table 2). Distributing all 
HIVST kits through other modalities was more costly 
compared with the status quo, having an estimated 
incremental cost ranging between $198 million (for taxi 
ranks) and $1.6 billion (for distribution to partners of 
ART patients) over 20 years.
Cost-effectiveness
Scenario A
With the exception of workplace distribution, which was 
cost- saving, the HIVST distribution modality with the 
lowest incremental cost effectiveness ratio (ICER) over 
20 years was distribution through taxi ranks ($194/life 
year saved and $438/HIV infection averted) (figure 1, 
table 2). Fixed point distribution was the second most 
cost- effective ($705/life year saved and $3092/HIV infec-
tion averted), while secondary distribution through ART 
patients and ANC clients were the least cost- effective 
distribution modalities ($1394 and $2899/life year saved, 
respectively) (table 2).
Scenario B
Increasing distribution of HIVST kits up to 6.7 million 
and directing it all to taxi ranks had the lowest ICER 
relative to the other distribution modalities, compared 
with the status quo ($2030/life year saved and $4019/
HIV infection averted), whereas secondary distribution 
to partners of ANC clients and ART patients at PHC 
were the least cost effective ($4162/life year saved and 
$14 688/HIV infection averted) (figure 1, table 2). 
The relative cost- effectiveness of secondary distribution 
to partners of ANC clients differed from scenario A as 
these clients were limited to a feasible maximum limit 
of 1.2 million people who could receive HIVST, thereby 
curtailing the incremental cost and impact overall.
Optimisation
Scenario A
Distributing the majority (IQR 38%–63%) of the 1 million 
HIVST kits through workplaces led to cost savings over 20 
years, compared with the status quo distribution; LYS was 
estimated to range between 100 and 24 000 (figure 2A). 
Beyond the cost- saving configurations, ICER/LYS 
was lowest when a large portion of HIVST kits were 
















% of kit recipients screened positive   5.7% 5.2% 3.9% 19.9% 6.4% 4.0%
% of screened positive initiating ART   27% 27% 27% 27% 27% 40%
Cost per test kit distributed (2019 US$) – 5.70 4.74 13.04 12.31 5.44 8.24
Distribution of HIVST into different modalities           
  Fixed point 5% 100% – – – – –
  Taxi ranks 5% – 100% – – – –
  Secondary PHC (ANC) 7% – – 100% – – –
  Secondary PHC (ART patients) 3% – – – 100% – –
  Workplace 20% – – – – 100% –
  Primary PHC 60% – – – – – 100%
Scenario A: Distributing 1 million HIVST per year
  Total HIV tests performed per year (millions) 15.4 15.5 15.5 15.6 15.4 15.5 15.3
  HTS 14.5 14.6 14.7 14.8 14.9 14.6 14.3
  HIVST 0.9 0.9 0.9 0.8 0.5 0.9 1.0
  % of tests that are HIVST 6% 6% 5% 5% 4% 6% 7%
Scenario B: Distributing up to 6.7 million HIVST per year (to replace 40% of conventional HTS)
  Total HIV tests performed per year (millions) 15.4 15.9 15.7 15.6 15.9 15.8 15.3
  HTS 14.5 9.6 12.4 14.4 10.5 9.5 9.0
  HIVST 0.9 6.3 3.3 1.2 5.4 6.3 6.3
  % of tests that are HIVST 6% 40% 21% 8% 34% 40% 41%
ANC, antenatal care; ART, antiretroviral therapy; HIVST, HIV self- testing; HTS, HIV testing services; PHC, primary healthcare.
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distributed to workplaces (IQR 13%–38%), while there 
was a mixed distribution for the other modalities: IQR 
0%–38% each for fixed point and taxi rank distribution, 
IQR 0%–25% each for secondary distribution to partners 
of ART patients and primary distribution to PHC clients, 
while secondary distribution to partners of ANC clients 
Figure 1 Impact and cost- effectiveness of redistribution all HIVST to different testing strategies, 2020–2039. For distributing 
1 million HIVST annually, impact on HIV infections averted (A) and life years saved (B); for distributing up to 6.7 million HIVST 
annually, impact on HIV infections averted (C) and life years saved (D). Bubble size represents the number of HIVST distributed 
to each population annually. HIVST, HIV self- testing.
Figure 2 (A) Number of life years saved over the status quo and (B) incremental cost- effectiveness ratio, incremental cost 
per life year saved (2019 US$), distributing up to 1 million HIVST distributed per year. Status quo: 1 million HIVST distributed to 
fixed point (5% of HIVST), taxi ranks (5%), secondary PHC (ANC) (7%), secondary PHC (ART patients) (3%), workplace (20%) 
and primary PHC distribution (60%). ANC, antenatal care; ART, antiretroviral therapy; HIVST, HIV self- testing; PHC, primary 
healthcare.
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had the lowest allocation (IQR 0%–13%) (figure 2B). 
The biggest epidemiological impact resulted from 
distributing the majority of HIVST (IQR 50%–75%) to 
partners of ART patients (ranging between 32 000 and 
46 000 LYS), and these configurations were in the higher 
range of ICERs with an IQR of $2100–$2600 per life year 
saved (figure 2B). Configurations of HIVST distribution 
relying mainly on secondary distribution to partners of 
ANC clients (IQR 25%–63%) or primary PHC distribu-
tion (13%–50%) were the least cost- effective, with ICERs 
upwards of $4000 per life year saved, and even dominated 
(if 60% or more of HIVST was distributed to primary 
PHC) (figure 2B). Similar patterns were obtained when 
using HIV infections averted as an outcome (online 
supplemental appendix figure S1).
Scenario B
In comparison to the status quo distribution of 1 million 
HIVST kits distributed annually, if scaled up to 6.7 million 
HIVST annually, the largest impact was achieved when 
most HIVST kits (IQR 55%–64%) were distributed to 
partners of ART patients, saving between 200 000 and 
241 000 life years over 20 years, while ICERs for these 
configurations ranged between $2400 to $4300 per life 
year saved (figure 3A,B). Using the set of configurations 
that result in the median impact as the optimal distribu-
tion strategy, the optimal HIVST kit distribution would 
look as follows: 64% to partners of ART patients, 9% each 
epidemiological fixed point, taxi ranks and workplaces 
and none to partners of PHC ANC clients and primary 
PHC clients. Compared with the status quo distribution 
of 1 million HIVST annually, an optimised scale- up of 
distribution to 6.7 million tests annually would result in 
an almost threefold increase in LYS compared with the 
same volume scale- up at the current status- quo distri-
bution (table 2) (216 000 vs 75 000 LYS), and it would 
have a lower ICER ($3990 vs $4493 per LYS). Distribu-
tion to workplaces was cost- saving only when 100% of all 
HIVST were distributed through this modality, and it had 
a moderate impact: saving 137 000 life years over 20 years 
(figure 3). The distribution strategies with the lowest 
ICER/LYS were those where majority of HIVST kits were 
distributed to workplaces. Distributing more than 50% of 
HIVST kits to primary PHC showed the least impact rela-
tive to other configurations (<100 000 LYS), and it was the 
least cost- effective strategy, with ICERs upwards of $4000 
per LYS (figure 3A,B). We see similar patterns when 
analysing the impact on HIV infections averted (online 
supplemental appendix figure S2).
Comparing against a baseline of no HIVST
In scenario A, when comparing against a baseline with no 
HIVST, we see similar patterns of distribution configura-
tions where HIVST distributed mainly to partners of ART 
patients produced the largest epidemiological impact 
(ranging 75 000–93 000 LYS), while ICERs are upwards 
of $2000 per LYS (online supplemental appendix figure 
S3). HIVST distributed mostly (>50%) through secondary 
distribution to partners of ANC clients was the least cost- 
effective strategy with the highest ICERs among all config-
urations. Distributing most HIVST (>40%) to workplaces 
is the most cost- effective strategy, with ICERs falling below 
Figure 3 (A) Number of life years saved over the status quo and B) incremental cost- effectiveness ratio, incremental cost per 
life year saved (2019 US$), distributing up to ~6.7 million HIVST per year by 2030. Status quo: 1 million HIVST distributed to 
fixed point (5% of HIVST), taxi ranks (5%), secondary PHC (ANC) (7%), secondary PHC (ART patients) (3%), workplace (20%) 
and primary PHC distribution (60%). *Indicates single configuration where results are cost- savings (ie, 100% distribution to 
workplaces). ANC, antenatal care; ART, antiretroviral therapy; HIVST, HIV self- testing; PHC, primary healthcare.
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$1100 per life year saved (online supplemental appendix 
figure S3). When scaling up to 6.7 million HIVST kits 
distributed annually, compared with a baseline with no 
HIVST, distribution to partners of ART patients was the 
strategy that yielded the largest impact (>235 000 LYS), 
although it had high ICERs relative to the other config-
urations (>$3200/life year saved) (online supplemental 
appendix figure S4). Primary PHC distribution was the 
least cost- effective (>$4000/life year saved) and least 
impactful strategy (<165 000 life year saved). Workplace 
distribution was the most cost- effective strategy (ICER 
<$2000/life year saved) but had a moderate epidemio-
logical impact, ranging between 170 000 and 200 000 LYS 
(online supplemental appendix figure S4).
DISCUSSION
The distribution of HIVST kits is expected to have a large 
impact on averting new HIV infections and AIDS deaths 
over 20 years, compared with a baseline status quo where 
HIVST kits were already distributed through different 
modalities with a set distribution pattern (60% to primary 
PHC, 20% to workplaces, 7% to secondary distribution to 
partners of ANC clients in PHC, 5% to taxi ranks, 5% 
to fixed point and 3% to secondary distribution to part-
ners of ART patients). Importantly, we have shown the 
importance in determining the optimal configuration of 
testing modalities as HIVST scales up. An optimisation- 
informed scale- up—instead of proportionally scaling- up 
the current distribution of HIVST testing modalities—is 
expected to nearly triple the number of LYS. Redirecting 
all HIVST towards any distribution strategy other than 
primary PHC performs better in terms of saving life 
years and averting HIV infections over 20 years than 
the planned status quo; however, results vary in terms of 
costs and cost effectiveness. We showed that secondary 
distribution to partners of ART patients will have the 
biggest epidemiological impact but will be the least cost- 
effective strategy due to its high cost, while distribution 
of HIVST to workplaces will be cost- saving but have only 
a moderate impact on averting HIV infections. Distri-
bution to primary PHC is not cost- effective due to the 
lower HIV positivity yielded and may even be dominated 
compared with other distribution strategies.
There are several limitations to this work. First, cost 
data for the different distribution strategies were based 
on an initiative that was managed and implemented by 
non- governmental organisations, and therefore both cost 
and screening positivity could change once introduced 
and managed in the public sector. Second, for primary 
PHC testing, we assumed the same screening positivity 
as conventional HTS. It is plausible that screening posi-
tivity could be higher if implemented in the real world 
as PHC clients concerned about their HIV status might 
prefer self- screening over conventional HTS within 
the clinic setting to avoid stigma or have more control 
over the testing procedure. However, we do posit the 
screening positivity of primary PHC to remain lower 
than those of the higher performing distribution strat-
egies, and indeed this was shown to be the case in the 
vertical, non- integrated PHC testing strategy included 
in Matsimela et al.18 Third, the model estimates of HIV 
testing yields were in some cases inconsistent with those 
reported in the STAR data, suggesting that matching the 
age and sex profile of HIV test recipients may be insuffi-
cient to reasonably capture the different HIV risk profiles 
associated with different testing modalities. However, the 
STAR data are not nationally representative, and imple-
mentation has not been uniform, with different HIVST 
modalities being piloted in different areas by different 
implementers. Some divergence between observed 
testing yields and yields estimated in a national model 
is therefore to be expected, and it will be important to 
continue to monitor testing yields as different HIVST 
modalities are scaled up nationally.
Future work on HIVST should include the evaluation 
of the different testing strategies once scaled up in the 
public health system to understand the real cost and 
screening positivity. The positivity rate may decline differ-
entially between testing modality as demand saturates, 
and therefore understanding the optimal timing and 
frequency of testing by modality will need to continue in 
order to help guide effective implementation.
CONCLUSION
In evaluating the impact and cost- effectiveness of 
different HIVST distribution modalities using a HIV 
transmission model and data collected alongside large- 
scale routine implementation under the STAR initiative, 
we were able to generate findings that could help inform 
policy makers making decisions on the most effective 
strategy to prioritise for national roll- out: the secondary 
distribution of HIVST to partners of ART patients. 
However, this will be a costly approach. The optimal 
distribution of HIVST is estimated to be a mix between 
secondary distribution of HIVST kits to partners of ART 
patients and pregnant women in care at PHC, workplace 
testing and fixed point HIVST distribution. Further, in 
the face of the global COVID-19 pandemic affecting all 
health services, including HIV testing, scaling up HIVST 
in order to limit patient contact with health services and 
providing an option of self- screening to those reluctant 
to attend a PHC clinic, would assist greatly in maintaining 
or increasing progress towards testing targets.
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